Quick Answer
Alzamend Neuro, Inc. reported Stockholders Equity of $3.97 million for the year ending 2025.
- Alzamend Neuro, Inc. showed an increase of +253.0% in Stockholders Equity from 2024 to 2025.
- This data is from Alzamend Neuro, Inc.'s annual report (Form 10-K), filed with the SEC on July 22, 2025.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $25.9 thousand | Q4 2020: -$666.8 thousand | Q1 2021: -$1.30 million | Q3 2021: $15.34 million | Q4 2021: $13.03 million | Q1 2022: $11.96 million | Q2 2022: $13.35 million | Q3 2022: $11.18 million | Q4 2022: $8.79 million | Q1 2023: $5.86 million | Q3 2023: -$112.9 thousand | Q4 2023: -$2.68 million | Q1 2024: -$4.26 million | Q2 2024: -$2.59 million | Q3 2024: -$1.21 million | Q4 2024: $3.75 million | Q1 2025: $3.45 million | Q2 2025: $3.97 million | Q3 2025: $5.34 million | Q4 2025: $4.37 million.
- Over the full 7 years of available data (2019 to 2025), Alzamend Neuro, Inc.'s Stockholders Equity has grown by 1,152.1%.
- Historical annual values: Fiscal year 2025: $3.97 million | Fiscal year 2024: -$2.59 million | Fiscal year 2023: $3.05 million | Fiscal year 2022: $13.35 million | Fiscal year 2021: $2.01 million | Fiscal year 2020: $821.7 thousand | Fiscal year 2019: $316.9 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: